Literature DB >> 1399232

Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors.

C J Stewart1, O J Owens, J A Richmond, A M McNicol.   

Abstract

Increased expression of epidermal growth factor (EGF) receptor has been recorded in many types of human tumors and has been associated with reduced survival in ovarian carcinoma. The purpose of this study was to examine the immunocytochemical distribution of the EGF receptor in normal ovaries (n = 30) and in ovarian tumors (n = 126). Staining was observed in two normal ovaries, in the granulosa cells of a developing follicle, and in surface epithelium. Forty-seven of 103 malignant common epithelial tumors were immunopositive. Staining was usually focal, always confined to the neoplastic epithelium, and showed a cytoplasmic distribution. There was a slight trend for increased EGF receptor expression in more advanced common epithelial malignancies, but this was not statistically significant. No correlation between immunoreactivity and histological subtype or grade of tumor was seen. A few other tumors were also examined: one each of Brenner tumor, mature teratoma, mature teratoma with squamous carcinoma, borderline serous tumor and fibroma; all were immunopositive.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399232     DOI: 10.1097/00004347-199210000-00004

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.

Authors:  Karen D Cowden Dahl; Richard Dahl; Jessica N Kruichak; Laurie G Hudson
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

2.  PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

Authors:  Karen D Cowden Dahl; Reema Zeineldin; Laurie G Hudson
Journal:  Mol Cancer Res       Date:  2007-05-02       Impact factor: 5.852

3.  EGFR soluble isoforms and their transcripts are expressed in meningiomas.

Authors:  Angélique Guillaudeau; Karine Durand; Barbara Bessette; Alain Chaunavel; Isabelle Pommepuy; Fabrice Projetti; Sandrine Robert; François Caire; Hélène Rabinovitch-Chable; François Labrousse
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

4.  Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

Authors:  F McPhillips; P Mullen; B P Monia; A A Ritchie; F A Dorr; J F Smyth; S P Langdon
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

5.  ARID3B Directly Regulates Ovarian Cancer Promoting Genes.

Authors:  Alexander Bobbs; Katrina Gellerman; William Morgan Hallas; Stancy Joseph; Chao Yang; Jeffrey Kurkewich; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

6.  ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death.

Authors:  Stancy Joseph; Victoria E Deneke; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

7.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

Authors:  G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.